Takeaways: The approval should help Kardium gain early adoption in Canada by offering a single-catheter solution that combines high-density mapping and PFA with strong PULSAR data (78%...
Takeaways: The C-POST data – 68% reduction in recurrence or death versus placebo – gives Regeneron a strong clinical story to push Libtayo earlier in the treatment pathway,...
Takeaways: The availability of a nasal spray should broaden the addressable market for emergency epinephrine by reducing needle anxiety and administration hesitation, potentially increasing carr...
Takeaways: The decision should expand use of Keytruda plus enfortumab vedotin in the perioperative setting by giving oncologists a data-backed option that improves event-free...
Takeaways: The decision is especially meaningful for CELYSTRA because Québec is a high-prevalence region for FCS among French Canadians, so public coverage can quickly translate into concentrate...
Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
Takeaways: Aspen-Semaglutide’s approval introduces the generic Ozempic-equivalent into Canada’s GLP‑1 space, setting up price competition and broader access in type 2 diabetes once API supply co...
Takeaways: The licensing of Alethia CMV gives Meridian a saliva-based, rapid molecular test for congenital CMV that can be deployed in the hours after birth, shifting detection from delayed or i...
Takeaways Health Canada’s approval of Novartis’ Vanrafia (atrasentan) creates Canada’s first endothelin receptor antagonist–based therapy specifically for IgA nephropathy, giving clini...
Takeaways Dexcom G7 15 Day’s Health Canada authorization sets up a step-change in CGM economics and adoption once launched, by extending wear to 15.5 days and offering top-tier accuracy and dire...
